4P-Pharma lands €15m to advance therapies for osteoarthritis, dry AMD and more

Biotech initiates Phase 2 development of osteoarthritis program as it seeks to spin-out new companies in multiple therapeutic areas.

French biotech 4P-Pharma has secured €15 million in new funding as it advances multiple programs seeking curative therapies for serious untreated diseases. Via its “startup studio” model, the Lille-based company creates new spinout companies tackling a wide range of therapeutic areas, including chronic and autoimmune diseases, respiratory and infectious diseases, preventive therapies and ophthalmological conditions.

The new funding, sourced from “private investors,” will further support the advancement of 4P-Pharma’s internal pipeline, particularly the Phase 2 clinical development of its first spinouts. The company says the infusion of capital also provides the necessary runway to pursue external growth opportunities through mergers and acquisitions and licensing-in initiatives.

Among its development programs, 4P-Pharma has developed 4P004, a GLP-1 analog designed as a potential disease modifier drug for osteoarthritis. Developed in collaboration with institutions including St-Antoine’s Hospital in Paris and Sorbonne University, the company says that 4P004 has shown promising anti-inflammatory, analgesic, and cartilage protection/regeneration properties in preclinical studies. Having completed Phase 1 studies, 4P004 is being prepared for Phase 2 by a spinout called 4Moving Biotech.

Another of 4P-Pharma’s longevity-related programs, 4P020, is a beta-3 adrenergic receptor agonist, represents a novel therapeutic approach for dry age-related macular degeneration (AMD), a condition expected to affect millions worldwide by 2040.

“After a decade of existence, 4P-Pharma is opening a novel turning point of its growth,” said Revital Rattenbach, CEO of 4P-Pharma. “This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community.”

Photograph: paegagz/Envato